NL-OMON42814已完成4 期
Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial. - Tight control dose decrease of biologics for psoriasis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Sustained low disease activity (PASI<5 for at least 6 months, DLQI<5 at inclusion) on the regular dose as advised by the label.;* Established diagnosis of plaque psoriasis.;* Receiving treatment with adalimumab, etanercept, or ustekinumab for at least 6 months.;* Age *18 years.
排除标准
- •* Psoriasis itself is not the main reason for biologic prescription (e.g. when a patient has RA and psoriasis, and RA is the main reason for the biologic).;* Concomitant use of immunosupressants other than methotrexate or acitretin for psoriasis.;* Severe comorbidities with short life-expectancy (e.g. metastasized tumour).;* Presumed inability to follow the study protocol.
研究者
相似试验
进行中（未招募）
1 期
Dose decrease of biologics for psoriasisAdult Patients diagnosed psoriasis vulgarisMedDRA version: 18.1Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10015581Term: Exacerbation of psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037156Term: Psoriasis flare-upSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-000943-17-NLRadboudumc120
尚未招募
不适用
Dose decrease of biologics in psoriasis patients with low disease activity.psoriasis, biologics, tnf-alfa remmers, etanercept, adalimumab, ustekinumab, dosis reductie, dose reduction, dose decreaseNL-OMON24722Radboudumc, Nijmegen, The Netherlands120
进行中（未招募）
1 期
Dose reduction of IL17 and IL23 inhibitors for psoriasispsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004230-42-NLRadboudumc244
尚未招募
不适用
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON29024ZonMw, KCE244
招募中
4 期
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON52624Academisch Medisch Centrum142